In early 2026, the UK has introduced a legal mandate requiring all clinical trials to register in a public registry and share their results within 12 months of completion. This 2026 transparency initiative is a key part of the regulatory overhaul, intended to build public trust by ensuring that the outcomes of all research—whether positive or negative—are accessible to patients and...

The UK has cemented its reputation as a global leader in Advanced Therapeutic Medicinal Products (ATMPs), including cell, gene, and oligonucleotide therapies. This high-growth segment requires specialized clinical investigation expertise and robust regulatory pathways, making it a strategic area of focus within the drug development ecosystem. Government and industry investment is heavily...

The UK maintains a robust network of specialized Early-Phase Clinical Development Units (EPCDUs), often linked to major academic centers and dedicated to conducting complex Phase I and Phase II clinical trials. These units are critical because they handle the initial "first-in-human" studies that determine the safety, tolerability, and correct dosage of a novel therapeutic candidate. EPCDUs...